What does Huisheng Biology do?

Convertible bond subscriptions are relatively popular now, and the Huisheng Bonds purchased on December 17 are also very popular. The issuance quantity of this convertible bond is not large, and you can actively subscribe for it. It is good to apply online. It is very important to understand what Huisheng Biotech does when subscribing for Huisheng's bonds.

What does Wuhan Huisheng Biotechnology Co., Ltd. do?

The main business of Wuhan Huisheng Biotechnology Co., Ltd. is veterinary drugs (including chemical preparations, APIs, R&D, production and sales of traditional Chinese medicine preparations), feed and additives; the company's main products include Tylvalsin Tartrate, Tylvalsin Tartrate Premix, Florfenicol Powder, Florfenicol Injection, Doxanthin Hydrochloride Cyclin soluble powder, compound amoxicillin powder, amoxicillin soluble powder, tilmicosin premix, tiamulin fumarate premix, ceftiofur hydrochloride injection, compound sulfachloridazine sodium powder, tartaric acid Tylosin-sulfamethazine soluble powder, albendazole-ivermectin powder, Banqing granules, Dingchuan powder, compound premixed feed for piglets. The company obtained a new veterinary drug certificate for rifaximin uterine injection and a new veterinary drug certificate for gaminomycin.

1. The company's main business

With the mission of "committed to animal health technology and improving the quality of life", the company is mainly engaged in veterinary drugs (including chemical preparations, raw materials, and traditional Chinese medicines) preparations), feeds and additives. Mr. Zhang Weiyuan, the founder of the company, adheres to the concept of "doing one thing well in life". The company has focused on the field of veterinary drugs since its establishment and has a wealth of veterinary chemical preparations and core API production lines. As of November 30, 2021, it has achieved There are 143 veterinary drug approval numbers. The company focuses on pig drugs, covering various types of drugs such as anti-microbial and anti-parasitic drugs. "When pigs are sick, find the best solution" has established a high reputation in the industry. At the same time, the company has also expanded into other pharmaceutical fields such as poultry, aquatic products, pets, ruminant, etc., further enriching the product structure.

2. Main business model

The company has a complete procurement, research and development, production and sales system. The main income and profits come from the sales of veterinary drugs (including chemical preparations, raw materials, and traditional Chinese medicine preparations), feed and additives, and veterinary raw materials.

When will Huisheng Convertible Bonds be launched?

Huisheng Convertible Bonds were purchased on December 17, with an issuance of 700 million yuan, a credit rating of AA-, and a conversion price of 28.32. Rights: The rights per share are 4.2105, which belongs to the Shenzhen stock market. There is a high probability that 300 shares can be allocated to 13 convertible bonds, which is about 8,500 yuan. It does not require much funds. It is expected that the profit of one convertible bond is about 300 yuan. To withstand a drop of around 3.5, the safety cushion is pretty good.